Life Sciences Webinar: Inducing Infringement of Pharmaceutical Method of Treatment Claims

December 2, 2009 – December 4, 2009

Since the Court of Appeals for the Federal Circuit en banc decision in DSU Medical Corp. v. JMS Co. clarifying the requirements for inducement to infringe, proving inducement has been a challenging exercise. Nowhere is this more so than when enforcing pharmaceutical method of treatment claims against generic drug companies. 

In this Webinar, our speakers will discuss the current state of the law on enforcement of pharmaceutical method of treatment claims under the Hatch-Waxman litigation scheme, and will provide useful insights into how to tackle the issues that arise in proving the active inducement and the specific intent requirements articulated by the DSU Court.